I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Lung cancer is the leading cause of cancer-related mortality worldwide and represents a severe public health issue.\[[@ref1]\] Non-small cell lung cancer (NSCLC) is the major form and accounts for over 80% of all cases of lung cancers.\[[@ref2]\] Despite great treatment advances have been made over the past decades, the 5-year overall survival rate is only 16% for all stages of NSCLC.\[[@ref3]\] The initiation and progression of NSCLC are due to dysregulation of oncogenes and tumor-repressor genes. However, the molecular mechanisms underlying NSCLC have not been fully elucidated yet. Hence, it is important to identify new molecular mechanisms underlying the development of NSCLC and uncover novel therapeutic targets to improve the prognosis of patients with this disease.

MicroRNAs (miRNAs) are a class of short and noncoding RNA molecules that play critical roles in several biological processes such as proliferation, angiogenesis, apoptosis, cell differentiation, DNA damage repair, and stress responses.\[[@ref4]\] Previous studies suggested that aberrant expression of miRNAs, such as miR-128-3p, miR-608, miR-15a, and miR-16, contributes to the pathogenesis of NSCLC.\[[@ref5][@ref6][@ref7]\] However, articles about the role of iR-125b-1-3p in NSCLC are limited.

In this study, we evaluated the expression of miR-125b-1-3p in NSCLC tumor tissues and cell lines. Then, we forced expression of miR-125b-1-3p in NSCLC cells to investigate its functions. Bioinformatic analysis was applied to identify the potential targets of miR-125b-1-3p. Moreover, the effects of miR-125b-1-3p on STAT3 signaling pathway were evaluated as well.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Informed consents were obtained from all participants.

Patient samples and cell culture {#sec2-2}
--------------------------------

From January 2015 to October 2017, 21 pairs of NSCLC biopsies and matched adjacent nontumor tissues were collected from patients at the First Affiliated Hospital of Wenzhou Medical University. All of the NSCLC patients were pathologically confirmed and tumor node metastasis (TNM) staging classifications were determined by the Union for International Cancer Control/American Joint Committee on Cancer 7^th^ edition for the lung. None of the patients received antitumor treatment before. Clinical characteristics of the patients are summarized in [Table 1](#T1){ref-type="table"}. All the samples were divided into a miRNA high expression group (*n* = 10) and low expression group (*n* = 11) using the median miR-125b-1-3p as the cutoff point. The NSCLC cell lines such as A549, H450, H1299, and 16-HBE normal lung bronchus epithelial cells were purchased from the American Type Culture Collection. Cells were cultured in RPMI-1640 medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Rockford, IL, USA), 100 U/L penicillin, and 100 μg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO~2~.

###### 

Correlation between miR-125-1-3p expression level and clinicopathological characteristics in NSCLC patients, *n*

  Characteristics         Low level (*n* = 11)   High level (*n* = 10)   *t*     *P*
  ----------------------- ---------------------- ----------------------- ------- -------
  Gender                                                                         
   Male                   4                      6                       0.582   0.279
   Female                 7                      4                               
  Age                                                                            
   \<60 years             5                      5                       0.074   0.835
   ≥60 years              6                      5                               
  Tumor size                                                                     
   \<3 cm                 4                      4                       0.387   0.864
   ≥3 cm                  7                      6                               
  TNM stage                                                                      
   I, II                  4                      5                       0.489   0.528
   III, IV                7                      5                               
  Histological grade                                                             
   Well/moderate          6                      7                       0.593   0.466
   Poor                   5                      3                               
  T stage                                                                        
   T0--T2                 2                      7                       4.324   0.017
   T3--T4                 9                      3                               
  Lymph node metastasis                                                          
   Yes                    8                      2                       7.332   0.016
   No                     3                      8                               

TNM: Tumor node metastasis; NSCLC: Non-small cell lung cancer.

RNA extraction, complementary DNA synthesis, and the quantitative real-time polymerase chain reaction {#sec2-3}
-----------------------------------------------------------------------------------------------------

Total RNA was extracted using TRIZOL reagent (Invitrogen, Waltham, MA, USA) followed by reverse transcription. Complementary DNAs were then used as templates for quantitative real-time polymerase chain reaction with iQ™ SYBR^®^ Green Supermix (Bio-Rad, Hercules, CA, USA). U6 was used as the control for normalization. Relative mRNA expression levels were calculated using the 2^−ΔΔCT^ method. All experiments were repeated at least three times.

Oligonucleotides {#sec2-4}
----------------

MiR-125b-1-3p mimic, a mimic control, miR-125b-1-3p antisense, and an antisense control were synthesized by the GenePharma Company (Suzhou, Jiangsu, China). A549cells were plated in six-well plates (4 × 10^5^ cells/well) for 24 h before transfection with miRNA or a plasmid using RNAiMAX (Life Technologies, Carlsbad, CA, USA) according to the manufacturer\'s instructions.

Cell Counting Kit-8 assay {#sec2-5}
-------------------------

The Cell Counting Kit-8 (CCK-8) assay was used to determine the viability of cells transfected with miR-125b-1-3p mimic, mimic control, miR-125b-1-3p antisense, and antisense control for 24, 48, or 72 h. All experiments were repeated at least three times.

Clonogenic assay {#sec2-6}
----------------

For the colony formation assay, 500 cells were plated in six-well plates and cultured in medium containing 10% fetal bovine serum. The medium was refreshed every 3 days. After incubation for 14 days, cells were fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich, St. Louis, MO, USA). Visible colonies were counted manually. Triplicate wells were measured for each group.

Cell migration and invasion assays {#sec2-7}
----------------------------------

For migration assay, cells were seeded in a serum-free medium in the upper Transwell chambers (Corning, New York, USA). Twenty-four hours later, cells were fixed with methanol and stained by 0.1% crystal violet. Migrated cells were counted under microscope and statistically analyzed. For invasion assay, Transwell chambers were coated with Matrigel (BD Bioscience, San Jose, CA, USA) to growth the cells for 24 h. Residual cells on the upper Transwell chamber were counted and statistically analyzed.

Cell apoptosis assays {#sec2-8}
---------------------

An Annexin V-FITC/propidium iodide (PI) Double Staining Kit (BD Biosciences, San Jose, CA, USA) was used to detect cellular apoptosis according to the manufacturer\'s instructions. Cells were collected, washed with cold phosphate-buffered saline, and resuspended at 1 × 10^6^ cells/ml in 1 ml binding buffer. Next, 5 μl Annexin V-FITC and 5 μl PI were added and incubated for 15 min at room temperature in the dark. Cells were detected by flow cytometry. All experiments were repeated three times.

Western blotting analyses {#sec2-9}
-------------------------

Cellular extracts were prepared by washing cells with phosphate-buffered saline and lysing in a lysis buffer containing a protease inhibitor. Protein concentrations were measured using Bradford protein assay kit (Beyotime, Haining, Jiangsu, China). Equal amounts of protein were loaded, separated by SDS-PAGE gel electrophoresis, and then transferred to PVDF membrane. Then, the membrane was blocked with 5% milk for 1 h at room temperature, they were incubated with following primary antibodies: caspase-3 (\#14220), Bcl-2 (\#2872), Mcl-1 (\#94296), Bax (\#2774), *S1PR1* (\#11424), p-STAT3 (\#4113), STAT3 (\#9196), and glyceraldehyde-3-Phosphate Dehydrogenase (\#2118) (Cell Signaling Technology, Danvers, MA, USA), followed by incubation with horseradish peroxidase-conjugated secondary antibodies: antimouse (\#7076) and antirabbit (\#7074; Cell Signaling Technology, Danvers, MA, USA). Protein bands were visualized using an enhanced chemiluminescent substrate (Thermo Scientific, Rockford, IL, USA). Protein bands were quantified by densitometric analysis using Quantity One software (Bio-Rad Laboratories, San Diego, CA, USA).

Caspase-3 activity assay {#sec2-10}
------------------------

Caspase-3 activity was determined using a Caspase-3 Colorimetric Activity Assay Kit (Beyotime, Haining, Jiangsu, China) according to the manufacturer\'s guidelines. Briefly, cells were collected, washed, lysed, and centrifuged. Sample lysates containing 50 μg of protein were assayed for caspase-3 activity. Absorbance was measured at 405 nm using a microplate reader (BioTek, Winooski, VT, USA).

Luciferase assays {#sec2-11}
-----------------

The sequence in the 3'-untranslated region (UTR) of the human *S1PR1* gene targeted by miR-125b-1-3p was predicted using microRNA.org (<http://www.microrna.org/>). The 3'-UTR of *S1PR1* and a sequence with mutations of two nucleotides in the miR-125b-1-3p target site were cloned into a pGL3 promoter vector to generate the recombinant constructs: wild-type and mutant 3'-UTRs, respectively. For the luciferase assay, A549 cells were co-transfected with wild-type and mutant 3'-UTRs of *S1PR1* and the miR-125b-1-3p mimic or scrambled controls (NC). Luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System according to the manufacturer\'s instructions (Promega, Madison, WI, USA) at 48 h posttransfection.

Statistical analyses {#sec2-12}
--------------------

All statistical analyses were performed using SPSS 18.0 software (IBM, Chicago, IL, USA). Data from at least three independent experiments, each performed in triplicate, were presented as means ± standard deviation (SD). Significant differences between groups were estimated using a one-way analysis of variance (ANOVA). A *P* \< 0.05 was considered as statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Expression levels of miR-125b-1-3p in non-small cell lung cancer samples and cell lines {#sec2-13}
---------------------------------------------------------------------------------------

Twenty-one pairs of NSCLC biopsies and matched adjacent nontumor tissue were analyzed. In addition, we detected miR-125b-1-3p expression levels in NSCLC cell lines (A549, H450, and H1299) and in 16-HBE normal lung bronchus epithelial cells. The results showed that miR-125b-1-3p was downregulated significantly in the NSCLC samples (*t* = 5.112, *P* = 0.009; [Figure 1a](#F1){ref-type="fig"}) and in cell lines compared to the control group (H450, *t* = 2.156, *P* = 0.036; H1299, *t* = 4.278, *P* = 0.007; and A549, *t* = 5.462, *P* = 0.006, respectively, [Figure 1b](#F1){ref-type="fig"}). For further analysis, all the samples were divided into a miRNA high expression group (*n* = 10) and low expression group (*n* = 11) using the median miR-125b-1-3p as the cutoff point. The results showed that miR-125b-1-3p expression was not correlated with age (*t* = 0.074, *P* = 0.835), gender (*t* = 0.582, *P* = 0.279), tumor size (*t* = 0.387, *P* = 0.864), and TNM stages (*t* = 0.489, *P* = 0.528), but it was correlated with tumor stage (*t* = 4.324, *P* = 0.017) and lymph node metastasis (*t* = 7.332, *P* = 0.016; [Table 1](#T1){ref-type="table"}).

![Expression levels of miR-125b-1-3p in 21 pairs of NSCLC tissues and three different NSCLC cell lines. (a) Expression level of miR-125b-1-3p in 21 pairs of NSCLC biopsies and matched adjacent nontumor tissue. (b) Expression levels of miR-125b-1-3p in 16-HBE normal lung bronchus epithelial cells and NSCLC cell lines. \**P* \< 0.05, ^†^*P* \< 0.01, compared to the 16-HBE normal lung bronchus epithelial cells. NSCLC: Non-small cell lung cancer.](CMJ-131-1909-g001){#F1}

Effect of miR-125b-1-3p on cell growth, migration, invasion, and apoptosis *in vitro* {#sec2-14}
-------------------------------------------------------------------------------------

A549 cells were transfected successfully with miR-125b-1-3p mimic, mimic control, miR-125b-1-3p antisense, and antisense control. The expression levels of miR-125b-1-3p were upregulated (4.1 ± 0.23 folds vs. control, *t* = 5.125, *P* = 0.001) and decreased (15.20 ± 0.07% of control, *t* = 2.123, *P* = 0.021) after transfection with miR-125b-1-3p and miR-125b-1-3p antisense, respectively \[[Figure 2a](#F2){ref-type="fig"}\]. The CCK-8 and colony formation assays revealed that overexpression of miR-125b-1-3p significantly inhibited the proliferation of A549 cells compared to the controls (37.8 ± 9.1%, *t* = 3.191, *P* = 0.013; Figure [2b](#F2){ref-type="fig"} and [2c](#F2){ref-type="fig"}). The wound healing and Transwell invasion assays showed the migration and invasion cell numbers of the miR-125b-1-3p mimic group were significantly decreased to 42.3 ± 6.7% (*t* = 6.321, *P* = 0.003) and 57.6 ± 11.3% (*t* = 4.112, *P* = 0.001) of control, respectively \[Figure [2d](#F2){ref-type="fig"} and [2e](#F2){ref-type="fig"}\]. In addition, overexpression of miR-125b-1-3p significantly induced more apoptosis compared with the control group (2.76 ± 0.78 folds, *t* = 3.772, *P* = 0.001; [Figure 2f](#F2){ref-type="fig"}).

![Effect of miR-125b-1-3p on cell growth, migration, invasion, and apoptosis *in vitro*. A549 cells were transfected with miR-125b-1-3p mimic or miR-125b-1-3p antisense. (a) The relative expression of miR-125b-1-3p was detected by the quantitative real-time polymerase chain reaction. Cell viability (b), colony numbers (c), migration (d), invasion (e), and apoptosis (f) were assessed using the CCK-8, clonogenic, cell migration, invasion assays, and flow cytometry, respectively. \**P* \< 0.05; ^†^*P* \< 0.01; ^‡^*P* \< 0.001. CCK-8: Cell Counting Kit-8.](CMJ-131-1909-g002){#F2}

MiR-125b-1-3p regulates apoptosis-related proteins {#sec2-15}
--------------------------------------------------

Apoptosis-related proteins were detected using Western blotting to further reveal the mechanism by which miR-125b-1-3p-induced apoptosis. Overexpression of miR-125b-1-3p caused cleavage of caspase-3 and significantly increased its activity (1.81 ± 0.42 folds vs. control, *t* = 2.323, *P* = 0.012; Figure [3a](#F3){ref-type="fig"} and [3b](#F3){ref-type="fig"}). At the same time, miR-125b-1-3p overexpression downregulated the antiapoptotic proteins, Bcl-2 (47.1 ± 4.2% of control; *t* = 3.182, *P* = 0.007) and Mcl-1 (45.5 ± 2.8% of control, *t* = 4.112, *P* = 0.008) but upregulated the pro-apoptotic protein, Bax (2.72 ± 0.14 folds vs. control, *t* = 4.791, *P* = 0.001; [Figure 3c](#F3){ref-type="fig"}).

![miR-125b-1-3p regulates apoptosis-related proteins. Caspase-3 (a) activity, cleaved caspase-3 levels (b), and protein levels of Bcl-2, Mcl-1, and Bax (c) were detected in A549 cells transfected with miR-125b-1-3p mimic or miR-125b-1-3p antisense. \**P* \< 0.01. ^†^*P* \< 0.001. compared to the control group.](CMJ-131-1909-g003){#F3}

MiR-125b-1-3p directly targets the S1PR1 gene {#sec2-16}
---------------------------------------------

Potential targets of miR-125b-1-3p were predicted by TargetScan. [Figure 4a](#F4){ref-type="fig"} shows the potential miR-125b-1-3p binding sites in the *S1PR1* mRNA 3'-UTR. We constructed mutations of the miR-125b-1-3p binding site in the *S1PR1* 3'-UTR of mRNA luciferase reporter. The miR-125b-1-3p mimic significantly reduced the relative luciferase activity of the wild-type 3'-UTR of *S1PR1* compared with the scrambled control (34.3 ± 2.4% of control, *t* = 5.143, *P* = 0.000) but did not affect the mutated luciferase reporter \[[Figure 4b](#F4){ref-type="fig"}\]. In addition, protein levels of *S1PR1* were reduced significantly in the miR-125b-1-3p mimic group compared to the mimic control (27.4 ± 6.1% of control, *t* = 4.081, *P* = 0.007), while the miR-125b-1-3p antisense group showed the opposite effect (1.22 ± 0.63 folds vs. control, *t* = 2.181, *P* = 0.032). This demonstrated that miR-125b-1-3p directly targeted the *S1PR1* gene \[[Figure 4c](#F4){ref-type="fig"}\].

![miR-125b-1-3p directly targets the *S1PR1* gene. (a) Wild-type and mutations of miR-125b-1-3p binding sites in the *S1PR1* mRNA 3′-UTR (red mark: seed region). (b) The luciferase assay was performed in A549 cells transfected with wild-type and mutant 3′-UTRs in the *S1PR1* gene together with miR-125b-1-3p mimic or scrambled controls. (c) *S1PR1* protein levels were detected by Western blotting in A549 cells transfected with miR-125b-1-3p mimic or miR-125b-1-3p antisense. \**P* \< 0.05, ^†^*P* \< 0.01, ^‡^*P* \< 0.001. UTR: Untranslated region.](CMJ-131-1909-g004){#F4}

MiR-125b-1-3p affecting the STAT3 phosphorylation status {#sec2-17}
--------------------------------------------------------

The effects of miR-125b-1-3p on the phosphorylation level of STAT3 were determined by Western blotting. We first transfected A549 cells with *S1PR1* siRNA to knock down *S1PR1* expression. [Figure 5a](#F5){ref-type="fig"} shows that *S1PR1* was successfully downregulated in the *S1PR1* siRNA group (12.33 ± 0.14% of control, *t* = 3.621, *P* = 0.004) and the miR-125b-1-3p mimic group (48.38 ± 0.12% of control, *t* = 2.163, *P* = 0.022). At the same time, the phosphorylation level of STAT3 was obviously decreased in the *S1PR1* siRNA (16.42 ± 0.14% of control, *t* = 3.021, *P* = 0.015) and miR-125b-1-3p mimic groups (16.71 ± 0.17% of control, *t* = 4.162, *P* = 0.026), respectively \[Figure [5a](#F5){ref-type="fig"} and [5b](#F5){ref-type="fig"}\]. Conversely, the level of phosphorylated STAT3 obviously increased in the anti-miR-125b-1-3p group compared with the control groups (2.64 ± 0.84 folds, *t* = 5.332, *P* = 0.004). However, the total levels of STAT3 were not affected. Thus, miR-125b-1-3p affects the phosphorylation status of STAT3.

![miR-125b-1-3p affects the phosphorylation status of STAT3. (a) Protein levels of S1PR1, and phosphorylated and total levels of STAT3, were detected by Western blotting in A549 cells transfected with *S1PR1* siRNA, miR-125b-1-3p mimic, miR-125b-1-3p antisense, or their corresponding control vectors. (b) Relative ratios of S1PR1to GAPDH and phospho (p)-STAT3 to total STAT3, \**P* \< 0.05, ^†^*P* \< 0.01. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.](CMJ-131-1909-g005){#F5}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The prevalence of NSCLC is increasing worldwide, and the prognosis of NSCLC patients remains poor. Therefore, improved therapeutic strategies for NSCLC patients are vital for the management of NSCLC. In recent years, miRNAs have emerged as potential antitumor agents due to its ability to affect the development of various types of cancers including NSCLC.\[[@ref9]\] Indeed, a better clarification of the functions of miRNAs in the pathogenesis of NSCLC may help in the search for more effective NSCLC therapies.

MiR-125b-1-3p has been found to play an important role in cancer and immunosuppression.\[[@ref10]\] MiR-125b-1-3p was reportedly downregulated significantly in Kaposi\'s sarcoma.\[[@ref11]\] In contrast, miR-125b-1-3p was found elevated in DICER1-mutated pleuropulmonary blastoma.\[[@ref12]\] This study found that miR-125b-1-3p was downregulated in NSCLC cells. Those discrepancies may be due to different cancer types, since mounting evidences indicate that miRNAs are highly tissue specific and can act as either oncogenes or tumor suppressors.\[[@ref13][@ref14]\] For instance, miR-205 can play a dual role, depending on the specific tumor type and target genes.\[[@ref15]\] Therefore, further investigations of miR-125b-1-3p in more cancer types are necessary. Noteworthy, we also revealed that miR-125b-1-3p exerts antitumor effects at least partly through induction of apoptosis. Dysregulated apoptosis is a common cause of cancer, and the treatment of NSCLC is usually impeded by the intrinsic or acquired resistance to apoptosis induced by anticancer agents.\[[@ref16]\] Many studies revealed that miRNAs could overcome the resistance to chemotherapy in NSCLC. For example, miR-101 could enhance paclitaxel (PTX)-induced apoptosis in NSCLC.\[[@ref17]\] MiR-216b was able to sensitize NSCLC cells to cisplatin-induced apoptosis.\[[@ref18]\] Moreover, miR-129-5p could also overcome resistance to cisplatin in NSCLC cells.\[[@ref19]\] Hence, it would be interesting to investigate whether miR-125-1-3p also possesses the ability to overcome chemoresistance in NSCLC.

To understand the functional mechanism of miRNAs, it is critical to identify targets involved in their regulation. SIPR1 was further identified as a direct functional target of miR-125-1-3p in NSCLC cells. S1PR1 is a G-protein-coupled receptor of the bioactive lipid, sphingosine-1-phosphate (S1P).\[[@ref20][@ref21]\] Tumor cells secrete S1P, promoting growth, survival, motility, and metastasis through binding to S1PRs in a autocrine/paracrine manner.\[[@ref22]\] A very recent study showed that upregulation of S1PR1 could lead to the proliferation and invasion of NSCLC cells.\[[@ref23]\] Considering S1PR1 is the predominant one compared with other S1PRs in NSCLC cells, the ability of miR-125-1-3p to repress S1PR1 might be applied as a promising strategy against NSCLC.

Aberrant STAT3 signaling is often observed in various cancers including the NSCLC. Inhibition of STAT3 signals would reduce cell proliferation and increase apoptosis of cancer cells. Many studies have been conducted to investigate the correlation between miRNAs and STAT3. For instance, miR-206 could inhibit STAT3 signaling and thereby attenuates the growth and angiogenesis of NSCLC cells.\[[@ref24]\] MiR-124 inhibits the proliferation of NSCLC cells and functions as a tumor suppressor through targeting STAT3.\[[@ref25]\] MiR-9600 regulates tumor progression and promotes PTX sensitivity in NSCLC through altering expression of STAT3.\[[@ref26]\] These studies suggest that STAT3 is subjected to the regulation of various miRNAs. In this study, we found that miR-125-1-3p was also involved in the STAT3 signaling pathway. Although the mechanisms of how miR-125-1-3p affects the STAT3 signaling are not fully revealed in this study. Given that *S1PR1* is crucial for the activation of STAT3 in cancer cell.\[[@ref27]\] MiR-125-1-3p may affect the STAT3 signaling through the regulation of S1PR1, and further investigations are needed to test this hypothesis.

There are limitations of this study. First, the number of samples in this analysis is relatively small. Second, there is a lack of survival analysis due to unable to collect the survival data of patients. Third, the investigation was performed based on cell lines and future *in vivo* analysis is needed. In summary, we revealed that miR-125b-1-3p was downregulated and function as a tumor suppressor in NSCLC. *S1PR1* was identified as a direct target of miR-125b-1-3p in NSCLC cells. Moreover, STAT3 signaling pathway was also affected by the miR-125b-1-3p. Our findings may help the development of novel therapeutic targets for the treatment of NSCLC patients.

Financial support and sponsorship {#sec2-18}
---------------------------------

This work was supported by the grants from the Natural Science Foundation of Zhejiang Province (No. LY14H160042) and Wenzhou Municipal Foundation of Science and Technology (No. Y20160049).

Conflicts of interest {#sec2-19}
---------------------

There are no conflicts of interest.

**Edited by:** Ning-Ning Wang
